Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

			December 31, 2021									December 31, 2020
(Dollars In thousands)	Estimated Remaining Useful Lives (Years)		Cost		Additions		Accumulated Amortization			Net Carrying Amount		Cost		Impairment			Accumulated Amortization			Foreign Currency Translation			Net Carrying Amount
In-process research    & development (1)	Indefinite-lived		$	—	$	—	$	—		$	—	$	4,212	$	(4,131	)	$	—		$	(81	)	$	—
Inbrija (2)		11		423,000		—		(87,164	)		335,836		423,000		—			(56,400	)		—			366,600
Website    development costs	1-3			14,559		26		(14,441	)		144		14,559		—			(14,178	)		—			381
			$	437,559	$	26	$	(101,605	)	$	335,980	$	441,771	$	(4,131	)	$	(70,578	)	$	(81	)	$	366,981

(1) Includes the fair value of BTT1023.

(2) In December 2018, the Company received FDA approval for Inbrija and accordingly reclassified the indefinite lived intangible assets to definite lived intangible assets and began amortizating the assets upon launch in February 2019.

Schedule of Estimated Future Amortization Expense for Intangible Assets

Estimated future amortization expense for intangible assets subsequent to December 31, 2021 is as follows:

(In thousands)
2022	$	30,894
2023		30,772
2024		30,768
2025		30,764
2026		30,764
Thereafter		182,018
	$	335,980